Search

Barlas Buyuktimkin Phones & Addresses

  • Phoenix, AZ
  • 2313 Willow Crk, Lawrence, KS 66049 (785) 749-2650
  • San Diego, CA
  • Robbinsville, NJ

Work

Company: University of kansas 2005 to 2011 Position: Graduate research assistant

Education

Degree: Ph.D. School / High School: University of Kansas 2008 to 2011 Specialities: Pharmaceutical Chemistry

Skills

Protein Chemistry • Circular Dichroism • Biochemistry • Hplc • Cell Culture • Mass Spectrometry • Sds Page • Fluorescence • Peptide Synthesis • Fluorescence Spectroscopy • Peptides • Protein Expression • Pcr • Drug Delivery

Industries

Higher Education

Resumes

Resumes

Barlas Buyuktimkin Photo 1

Lawrence, Kansas E RegiĆ£ O, Estados

View page
Location:
Phoenix, AZ
Industry:
Higher Education
Work:
University of Kansas 2005 - 2011
Graduate Research Assistant

BD Technologies May 2010 - Aug 2010
Summer Professional

University of Kansas Jun 2004 - Apr 2005
Pharmacy Student Intern

University of Kansas Jun 2003 - Aug 2003
Undergraduate Research Assistant
Education:
University of Kansas 2008 - 2011
Ph.D., Pharmaceutical Chemistry
University of Kansas 2005 - 2008
M.S., Pharmaceutical Chemistry
University of Kansas 1998 - 2005
Pharm.D., Pharmacy
Skills:
Protein Chemistry
Circular Dichroism
Biochemistry
Hplc
Cell Culture
Mass Spectrometry
Sds Page
Fluorescence
Peptide Synthesis
Fluorescence Spectroscopy
Peptides
Protein Expression
Pcr
Drug Delivery

Publications

Us Patents

Compositions Including I-Domain Antigen Conjugate Compounds And Methods For Treatment Of Autoimmune Disorders

View page
US Patent:
20130183327, Jul 18, 2013
Filed:
Jan 4, 2013
Appl. No.:
13/733991
Inventors:
UNIVERSITY OF KANSAS - Lawrence KS, US
Prakash Manikwar - Lawrence KS, US
Paul Kipkemboi Kiptoo - Lawrence KS, US
Ahmed Badawi - Overland Park KS, US
Barlas Buyuktimkin - Lawrence KS, US
John M. Stewart - Lawrence KS, US
Assignee:
UNIVERSITY OF KANSAS - Lawrence KS
International Classification:
C07K 14/47
US Classification:
4241851, 530409, 530408
Abstract:
The present disclosure provides IDAC compounds capable of presenting two or more signal 1 moieties to a host immune system and methods of using the IDAC compounds to treat or prevent autoimmune disorders in a subject. The present disclosure provides compounds including a modified I-domain peptide having two or more modified lysine residues and two or more signal 1 moieities conjugated to the modified lysine residues of the I-domain peptide and methods of using an making the compounds.
Barlas Buyuktimkin from Phoenix, AZ, age ~44 Get Report